Climb Bio (CLYM) Institutional Ownership $1.94 +0.06 (+3.19%) As of 10/15/2025 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Climb Bio (NASDAQ:CLYM)CurrentInstitutional OwnershipPercentage69.76%Number ofInstitutional Buyers(last 12 months)21TotalInstitutional Inflows(last 12 months)$43.59MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$568.41K Get CLYM Insider Trade Alerts Want to know when executives and insiders are buying or selling Climb Bio stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data CLYM Institutional Buying and Selling by Quarter Climb Bio Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025Shay Capital LLC415,000$515K0.1%+107.5%0.612% 8/14/2025Jane Street Group LLC148,180$184K0.0%N/A0.219% 8/14/2025Diadema Partners LP702,135$871K0.3%+4.8%1.039% 8/14/2025Qube Research & Technologies Ltd34,310$43K0.0%N/A0.051% 8/13/2025Marshall Wace LLP36,738$46K0.0%N/A0.054% 8/13/2025Stonepine Capital Management LLC116,147$144K0.1%N/A0.172% 8/12/2025JPMorgan Chase & Co.210,122$261K0.0%-31.4%0.311% 8/8/2025Geode Capital Management LLC311,721$387K0.0%-53.7%0.461% 8/8/2025Nan Fung Trinity HK Ltd.463,654$575K0.1%N/A0.686% 8/1/2025Y Intercept Hong Kong Ltd127,952$159K0.0%N/A0.189% 6/27/2025Goldman Sachs Group Inc.120,742$147K0.0%N/A0.179% 5/16/2025Goldman Sachs Group Inc.120,742$147K0.0%N/A0.179% 5/16/2025AQR Capital Management LLC21,808$27K0.0%N/A0.032% 5/16/2025Allostery Investments LP244,988$299K0.4%N/A0.363% 5/16/2025ADAR1 Capital Management LLC119,320$146K0.0%N/A0.177% 5/15/2025RA Capital Management L.P.31,419,267$38.33M0.6%N/A46.495% 5/14/2025Affinity Asset Advisors LLC1,500,000$1.83M0.2%N/A2.220% 5/13/2025Persistent Asset Partners Ltd145,760$178K0.1%N/A0.216% 5/12/2025Nuveen LLC39,034$48K0.0%N/A0.058% 5/9/2025Charles Schwab Investment Management Inc.70,093$86K0.0%N/A0.104% 5/8/2025XTX Topco Ltd27,660$34K0.0%N/A0.041% 5/7/2025TD Asset Management Inc89,400$109K0.0%N/A0.132% 4/30/2025Peapod Lane Capital LLC553,816$676K0.8%N/A0.821% 4/29/2025Bank of New York Mellon Corp64,914$79K0.0%N/A0.096% (Data available from 1/1/2016 forward) CLYM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CLYM shares? During the previous two years, 23 institutional investors and hedge funds held shares of Climb Bio. The most heavily invested institutionals were RA Capital Management L.P. ($38.33M), Affinity Asset Advisors LLC ($1.83M), Diadema Partners LP ($871K), Peapod Lane Capital LLC ($676K), Nan Fung Trinity HK Ltd. ($575K), Shay Capital LLC ($515K), and Geode Capital Management LLC ($387K).Learn more on Climb Bio's institutional investors. What percentage of Climb Bio's stock is owned by institutional investors? 69.76% of Climb Bio's stock is owned by institutional investors. Learn more on CLYM's institutional investor holdings. Which institutional investors have been buying Climb Bio's stock? Of the 21 institutional investors that purchased Climb Bio's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($31.42M), Affinity Asset Advisors LLC ($1.50M), Peapod Lane Capital LLC ($553.82K), Nan Fung Trinity HK Ltd. ($463.65K), Allostery Investments LP ($244.99K), Goldman Sachs Group Inc. ($241.48K), and Shay Capital LLC ($215K). How much institutional buying is happening at Climb Bio? Institutional investors have bought a total of 35,711,857 shares in the last 24 months. This purchase volume represents approximately $43.59M in transactions. Which of Climb Bio's major shareholders have been selling company stock? The following institutional investors have sold Climb Bio stock in the last 24 months: Geode Capital Management LLC ($362.09K), and JPMorgan Chase & Co. ($96.30K). How much institutional selling is happening at Climb Bio? Institutional investors have sold a total of 458,392 shares in the last 24 months. This volume of shares sold represents approximately $568.41K in transactions. Related Companies Fulcrum Therapeutics Institutional Ownership Ocugen Institutional Ownership Esperion Therapeutics Institutional Ownership Organogenesis Institutional Ownership ADC Therapeutics Institutional Ownership Inhibrx Biosciences Institutional Ownership CryoPort Institutional Ownership Solid Biosciences Institutional Ownership Rapt Therapeutics Institutional Ownership Astria Therapeutics Institutional Ownership This page (NASDAQ:CLYM) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
